David A. Siegel Cardiff Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 21,700 shares of CRDF stock, worth $45,136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,700
Previous 39,200
44.64%
Holding current value
$45,136
Previous $58,000
98.28%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRDF
# of Institutions
86Shares Held
8.48MCall Options Held
798KPut Options Held
39.2K-
Vanguard Group Inc Valley Forge, PA1.92MShares$4 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$1.93 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$1.42 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$1.41 Million0.0% of portfolio
-
Mai Capital Management551KShares$1.15 Million0.03% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $90.1M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...